Cleveland BioLabs, Inc. (NASDAQ:CBLI) rose 2.8% during trading on Friday . The company traded as high as $1.54 and last traded at $1.54. Approximately 222 shares traded hands during trading, a decline of 96% from the average daily volume of 5,378 shares. The stock had previously closed at $1.50.
A hedge fund recently raised its stake in Cleveland BioLabs stock. Renaissance Technologies LLC boosted its stake in shares of Cleveland BioLabs, Inc. (NASDAQ:CBLI) by 2.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 293,416 shares of the biotechnology company’s stock after purchasing an additional 6,100 shares during the period. Renaissance Technologies LLC owned about 2.60% of Cleveland BioLabs worth $493,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 3.85% of the company’s stock.
Cleveland BioLabs Company Profile (NASDAQ:CBLI)
Cleveland BioLabs, Inc, a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in radiation mitigation, oncology immunotherapy, and vaccines.
Recommended Story: Balanced Fund
Receive News & Ratings for Cleveland BioLabs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cleveland BioLabs and related companies with MarketBeat.com's FREE daily email newsletter.